1-5 of 5
Claire Crafter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Free
Chrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, Oona Delpuech, Jon O. Curwen, Larissa S. Carnevalli, Anna D. Staniszewska, Urszula M. Polanska, Azadeh Cheraghchi-Bashi, Mandy Lawson, Igor Chernukhin, Robert McEwen, Jason S. Carroll, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (5): 908–920.
https://doi.org/10.1158/1535-7163.MCT-17-0537
Published: 30 April 2018
View articletitled, Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
Open the PDF for Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Free
Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2441–2451.
https://doi.org/10.1158/1535-7163.MCT-15-0230
Published: 03 November 2015
View articletitled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Open the PDF for Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors in another window
Includes: Supplementary data
Journal Articles

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Free
Urs Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan, Rebecca Ellston, Hannah Dry, Claire Crafter, Bernard Barlaam, Martina Fitzek, Paul D. Smith, Donald Ogilvie, Celina D'Cruz, Lillian Castriotta, Stephen R. Wedge, Lara Ward, Steve Powell, Mandy Lawson, Barry R. Davies, Elizabeth A. Harrington, Emily Foster, Marie Cumberbatch, Stephen Green, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (1): 48–58.
https://doi.org/10.1158/1535-7163.MCT-14-0406
Published: 13 January 2015
View articletitled, Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Open the PDF for Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel in another window
Includes: Supplementary data
Journal Articles

Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo

Free
Christian Thomas, Francois Lamoureux, Claire Crafter, Barry R. Davies, Eliana Beraldi, Ladan Fazli, Soojin Kim, Daksh Thaper, Martin E. Gleave, Amina Zoubeidi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11): 2342–2355.
https://doi.org/10.1158/1535-7163.MCT-13-0032
Published: 06 November 2013
View articletitled, Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Open the PDF for Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo in another window
Includes: Supplementary data
Journal Articles

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Free
Barry R. Davies, Hannah Greenwood, Phillippa Dudley, Claire Crafter, De-Hua Yu, Jingchuan Zhang, Jing Li, Beirong Gao, Qunsheng Ji, Juliana Maynard, Sally-Ann Ricketts, Darren Cross, Sabina Cosulich, Christine C. Chresta, Ken Page, James Yates, Clare Lane, Rebecca Watson, Richard Luke, Donald Ogilvie, Martin Pass
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 873–887.
https://doi.org/10.1158/1535-7163.MCT-11-0824-T
Published: 08 April 2012
View articletitled, Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Open the PDF for Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background in another window
Includes: Supplementary data